摘要
胆系肿瘤是包括胆囊癌、肝内胆管癌和肝外胆管癌在内的一组异质性疾病,其起病隐匿、恶性程度高、进展迅速,预后很差,因此特别强调多学科综合治疗;而内科药物治疗,包括化疗和分子靶向治疗等,已经成为不可或缺的重要治疗手段。UK ABC-02临床研究的结果奠定了吉西他滨的重要地位,也打开了药物治疗的"阿里巴巴大门"。本文拟就胆系肿瘤的预后因素、辅助和新辅助化疗、姑息化疗和分子靶向治疗等问题,综述其现状和研究进展。
Billiary tract cancer is a group of heterogeneous disease, including extrahepatic cholangiocarcinoma, intrahepatic cholangiocarcinoma and gallbladder carcinoma. It has hidden onset, rapid progression, high degree of malignancy and poor prognosis, so multi-disciplinary treatment was emphasized. Medical treatment, including chemotherapy and molecular targeted therapy, has be- come one of the indispensable means. The results of UK ABC-02 clinical research laid the important position of gemcitabine and opened the door of drug treatment. This paper reviewed the current situation and research progress on the prognostic factors, neoadjuvant/adju- rant chemotherapy, palliative chemotherapy and molecular targeted therapy of billiary tract cancer.
出处
《临床肿瘤学杂志》
CAS
2013年第5期459-467,共9页
Chinese Clinical Oncology
关键词
胆系肿瘤
预后
内科治疗
进展
Biliary tract cancer
Prognosis
Medical treatment
Progress
